L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis

Ohara, Masatsugu; Ogawa, Koji; Suda, Goki et al.

Hepatology communications, 2018, 2(8), 910-922

Permalink : https://hdl.handle.net/2115/72965

このアイテムのアクセス数:726件（2026-08-15 10:17 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
1_Ohara_et_al-2018-Hepatology_Communications pdf 587 KB 740
2_hep41207-sup-0001-supinfos1 docx 15.1 KB 157 Supporting Information
3_hep41207-sup-0002-supinfos2 tif 4.70 MB 131 Supporting Information

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/72965
タイトル
L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
著者
Ohara, Masatsugu ; Ogawa, Koji ; Suda, Goki ; Kimura, Megumi ; Maehara, Osamu ; Shimazaki, Tomoe ; Suzuki, Kazuharu ; Nakamura, Akihisa ; Umemura, Machiko ; Izumi, Takaaki ; Kawagishi, Naoki ; Nakai, Masato ; Sho, Takuya ; Natsuizaka, Mitsuteru ; Morikawa, Kenichi ; Ohnishi, Shunsuke ; Sakamoto, Naoya
著者名
Ohara, Masatsugu
著者名
Ogawa, Koji
e-Rad_Researcher
20447460
著者名
Suda, Goki
著者名
Kimura, Megumi
著者名
Maehara, Osamu
著者名
Shimazaki, Tomoe
著者名
Suzuki, Kazuharu
著者名
Nakamura, Akihisa
著者名
Umemura, Machiko
著者名
Izumi, Takaaki
著者名
Kawagishi, Naoki
著者名
Nakai, Masato
著者名
Sho, Takuya
著者名
Natsuizaka, Mitsuteru
著者名
Morikawa, Kenichi
e-Rad_Researcher
10443475
著者名
Ohnishi, Shunsuke
e-Rad_Researcher
10334418
著者名
Sakamoto, Naoya
言語
英語
発行日
2018-08
出版者
John Wiley & Sons
収録物名
Hepatology communications
巻(号)
2(8)
ページ
910-922
抄録
Liver cirrhosis (LC) is a major cause of secondary sarcopenia. Sarcopenia makes the prognosis worse; thus, novel therapeutic options for sarcopenia in patients with LC are urgently required as they are currently limited. In this retrospective study, 158 patients with LC were screened, and 35 of those patients who were treated with L-carnitine for more than 6 months and for whom skeletal muscle mass changes could he evaluated by computer tomography were enrolled. Of the 158 patients, 79 patients who did not receive L-carnitine supplementation served as controls. Cases and controls were propensity score matched for age, sex, presence of hepatocellular carcinoma, and branched chain amino acid administration, and changes in skeletal muscle mass and clinical data were compared. The 35 patients who received L-carnitine supplementation and 35 propensity score-matched patients who did not receive carnitine supplementation comprised the final enrollment. Compared with control patients, patients who received L-carnitine had significantly worse liver function, which is associated with rapid progress of skeletal muscle depletion. However, loss of skeletal muscle mass was significantly suppressed in patients receiving L-carnitine, and a significant effect was observed in patient subgroups stratified by age, sex, presence of hepatocellular carcinoma, and branched chain amino acid administration. The change ratios of most laboratory data, including vitamin D and insulin-like growth factor 1 levels, were similar in the two groups, but ammonia levels were significantly less in those receiving L-carnitine. However, even in patients receiving L-carnitine but not showing an ammonia decrease, loss of skeletal muscle was significantly suppressed. Conclusion: L-carnitine suppresses loss of skeletal muscle mass and may therefore be a novel therapeutic option for sarcopenia in patients with LC.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
権利情報
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
PISSN
2471-254X
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1002/hep4.1207